Total Payments
$2.2M
2024 Payments
$169,242
Companies
50
Transactions
3,581
Medicare Patients
12,434
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$1.4M (65.0%)
Consulting$387,608 (17.8%)
Travel$241,461 (11.1%)
Food & Beverage$71,046 (3.3%)
Research$60,393 (2.8%)
Education$347.44 (0.0%)
Gifts$52.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 688 | 64.3% |
| Consulting Fee | $387,608 | 117 | 17.8% |
| Travel and Lodging | $241,461 | 707 | 11.1% |
| Food and Beverage | $71,046 | 2,025 | 3.3% |
| Unspecified | $60,393 | 10 | 2.8% |
| Honoraria | $15,665 | 7 | 0.7% |
| Education | $347.44 | 24 | 0.0% |
| Gift | $52.00 | 3 | 0.0% |
Payments by Type
General
$2.1M
3,571 transactions
Research
$60,393
9 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $433,906 | 695 | $0 (2024) |
| Lilly USA, LLC | $398,362 | 525 | $0 (2024) |
| ABBVIE INC. | $285,348 | 431 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $281,041 | 337 | $0 (2024) |
| UCB, Inc. | $162,700 | 328 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $96,494 | 77 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $91,665 | 125 | $0 (2024) |
| United Rheumatology | $82,537 | 12 | $0 (2021) |
| Radius Health, Inc. | $49,599 | 101 | $0 (2024) |
| Celgene Corporation | $43,760 | 101 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $169,242 | 297 | ABBVIE INC. ($66,943) |
| 2023 | $115,431 | 220 | AbbVie Inc. ($50,473) |
| 2022 | $337,885 | 534 | Janssen Scientific Affairs, LLC ($92,807) |
| 2021 | $131,195 | 364 | Lilly USA, LLC ($25,752) |
| 2020 | $176,170 | 277 | Amgen Inc. ($51,713) |
| 2019 | $403,263 | 710 | Amgen Inc. ($93,000) |
| 2018 | $409,305 | 609 | Lilly USA, LLC ($114,355) |
| 2017 | $432,393 | 570 | Amgen Inc. ($136,525) |
All Payment Transactions
3,581 individual payment records from CMS Open Payments — Page 1 of 144
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $44.93 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $31.18 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $5.45 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $24.70 | General |
| Category: Dermatology | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $8.55 | General |
| Category: Immunology | ||||||
| 12/11/2024 | UCB, Inc. | Cimzia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,425.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,425.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,425.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/06/2024 | Kyowa Kirin, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,560.00 | General |
| 12/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $10.22 | General |
| Category: Inflammation | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $673.92 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $25.49 | General |
| Category: RESPIRATORY | ||||||
| 11/25/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/25/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: Immunology | ||||||
| 11/22/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: Endocrinology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $7,980.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,425.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Etanercept monotherapy in PsA | Amgen Inc. | $47,303 | 4 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | UCB SA | $7,575 | 1 |
| A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | UCB SA | $2,525 | 1 |
| A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects With Active Ankylosing Spondylitis (CC-99677-AS-001) | Celgene Corporation | $1,211 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $179.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 2,662 | 3,694 | $360,157 | $252,537 |
| 2022 | 13 | 3,356 | 5,472 | $546,197 | $393,239 |
| 2021 | 14 | 3,066 | 5,077 | $493,785 | $359,121 |
| 2020 | 17 | 3,350 | 5,395 | $443,891 | $316,848 |
Total Patients
12,434
Total Services
19,638
Medicare Billing
$1.3M
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 667 | 969 | $136,573 | $97,406 | 71.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 714 | 1,045 | $104,542 | $72,355 | 69.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 336 | 418 | $41,754 | $29,609 | 70.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 126 | 149 | $20,971 | $14,690 | 70.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 85 | 100 | $19,708 | $13,878 | 70.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 86 | 86 | $11,919 | $7,744 | 65.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $6,971 | $4,675 | 67.1% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 100 | 100 | $4,452 | $4,465 | 100.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 410 | 586 | $2,930 | $2,871 | 98.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $3,625 | $2,308 | 63.7% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 36 | 115 | $4,600 | $1,065 | 23.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 35 | 58 | $922.20 | $740.08 | 80.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 18 | 19 | $1,191 | $728.61 | 61.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 880 | 1,553 | $221,010 | $163,825 | 74.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 921 | 1,664 | $168,232 | $119,759 | 71.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 126 | 199 | $39,783 | $30,564 | 76.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 258 | 370 | $37,362 | $24,300 | 65.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 118 | 152 | $21,822 | $15,116 | 69.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 152 | 152 | $20,195 | $13,656 | 67.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 75 | 75 | $14,366 | $10,590 | 73.7% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 106 | 106 | $4,617 | $4,615 | 99.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $6,100 | $4,509 | 73.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 608 | 1,033 | $5,165 | $3,057 | 59.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 33 | 39 | $2,468 | $1,697 | 68.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 24 | 24 | $1,838 | $855.21 | 46.5% |
About Dr. Robin Dore, MD
Dr. Robin Dore, MD is a Rheumatology healthcare provider based in Tustin, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1619972510.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robin Dore, MD has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $169,242 received in 2024. These payments were reported across 3,581 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, Dore has provided services to 12,434 Medicare beneficiaries, totaling 19,638 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Tustin, CA
- Active Since 06/16/2005
- Last Updated 09/28/2012
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1619972510
Products in Payments
- COSENTYX (Biological) $253,609
- Enbrel (Biological) $233,933
- RINVOQ (Biological) $148,651
- Cimzia (Drug) $135,018
- TALTZ (Drug) $113,209
- TREMFYA (Drug) $99,411
- SKYRIZI (Biological) $75,698
- Otezla (Drug) $71,159
- OLUMIANT (Drug) $71,130
- EVENITY (Biological) $63,708
- FORTEO (Drug) $55,623
- Tymlos (Biological) $49,467
- XELJANZ (Drug) $38,492
- Prolia (Biological) $38,484
- SIMPONI ARIA (Biological) $34,686
- KEVZARA (Drug) $30,605
- STRENSIQ (Biological) $23,354
- Humira (Biological) $21,895
- ORENCIA (Biological) $17,595
- Bimzelx (Biological) $17,077
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.